News
November 4, 2024
CTAD – LB25 – Plasma biomarker data indicates clinical activity of neflamapimod in dementia with Lewy bodies (DLB) is mediated through effects on the basal forebrain cholinergic system
Read More
July 29, 2024
Poster #91713: Neflamapimod treatment reduces plasma glial fibrillary acidic protein GFAP levels in patients with dementia with Lewy bodies (DLB) who do not have co-existing AD co-pathology
Read More
April 27, 2023
Presentation at AD/PD™ 2023 Conference on MRI Effects of Neflamapimod on the Basal Forebrain
Read More
February 20, 2023
EIP Pharma Founder and CEO John Alam, MD, provides corporate overview at 6th Annual Neuroscience Innovation Forum in San Francisco, January 8th, 2023
Read More
April 5, 2022
Presentation of CDR-SB Results in AscenD-LB Trial of Neflamapimod in DLB at AD/PD Conference on March 20th, 2022
Read More
About CervoMed
Are you a patient, caregiver, clinician or professional and want to learn more about CERVOMED’s approach? Please contact us.
Contact Us